Proteomics Analysis for Finding Serum Markers of Ovarian Cancer

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Cheng, Yushan ^a   Liu, Chongdong ^a   Zhang, Nawei ^a   Wang, Shengdian ^b   Zhang, Zhenyu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOL BINDING PROTEIN 4; TUMOR MARKER; PEPTIDE LIBRARY; PLASMA RETINOL BINDING PROTEIN; PROTEOME; RBP4 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; BREAST TUMOR; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MYOMA; OVARY CANCER; OVARY TUMOR; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; UPREGULATION; BLOOD; GENETICS; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PEPTIDE LIBRARY; PEPTIDE MAPPING; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADULT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEPTIDE LIBRARY; PEPTIDE MAPPING; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RETINOL-BINDING PROTEINS, PLASMA; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84930910572     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/179040     Document Type: Article

References (39)

1. R. E. Scully, R. H. Young, and P. B. Clement, "Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament, " Atlas of Tumor Pathology, vol. 3, p. 228, 1998.
2. L. A. G. Ries, M. P. Eisner, C. L. Kosary et al., SEER Cancer Statistics Review 1975-2002, National Cancer Institute, 2005.
3. A. Jemal, L. Clegg, E. Wardet al., "Annual report tothenationon the status of cancer, 1975-2001, with a special feature regardin survival, " Cancer, vol. 101, no. 1, pp. 3-27, 2004.
4. R. J. Kurman, K. Visvanathan, R. Roden, T. C. Wu, and I.-M. Shih, "Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis, " The American Journal of Obstetrics and Gynecology, vol. 198, no. 4, pp. 351-356, 2008.
5. J. Tiffen and S. M. Mahon, "Ovarian cancer screening: are there any options?" Clinical Journal of Oncology Nursing, vol. 9, no. 3, pp. 369-372, 2005.
6. H. Wang, M. T. Kachman, D. R. Schwartz, K. R. Cho, andD. M. Lubman, "Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers, " Proteomics, vol. 4, no. 8, pp. 2476-2495, 2004.
7. Z. Zhang, R. C. Bast Jr., Y. Yu et al., "Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer, " Cancer Research, vol. 64, no. 16, pp. 5882-5890, 2004.
8. E. F. Petricoin III, A. M. Ardekani, B. A. Hitt et al., "Use of proteomic patterns in serum to identify ovarian cancer, " The Lancet, vol. 359, no. 9306, pp. 572-577, 2002.
9. Y.-W. Lin, C.-Y. Lin, H.-C. Lai et al., "Plasma proteomic pattern as biomarkers for ovarian cancer, " International Journal of Gynecological Cancer, vol. 16, supplement 1, pp. 139-146, 2006.
10. R. C. Bast Jr., D. Badgwell, Z. Lu et al., "New tumor markers: CA125 and beyond, " International Journal of Gynecological Cancer, vol. 15, supplement 3, pp. 274-281, 2005.
11. M. J. Duffy, J. M. Bonfrer, J. Kulpa et al., "CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use, " International Journal of Gynecological Cancer, vol. 15, no. 5, pp. 679-691, 2005.
12. D. J. Hammond and J. T. Lathrop, "The discovery of trace therapeutic proteins fromcomplex biological materials, " Innovations in Pharmaceutical Technology, vol. 17, pp. 38-41, 2005.
13. F. Fortis, L. Guerrier, L. B. Areces et al., "A new approach for the detection and identification of protein impurities using combinatorial solid phase ligand libraries, " Journal of Proteome Research, vol. 5, no. 10, pp. 2577-2585, 2006.
14. E. Boschetti and P. G. Righetti, "Theart of observing rare protein species in proteomes with peptide ligand libraries, " Proteomics, vol. 9, no. 6, pp. 1492-1510, 2009.
15. L. Sennels, M. Salek, L. Lomas, E. Boschetti, P. G. Righetti, and J. Rappsilber, "Proteomic analysis of human blood serum using peptide library beads, " Journal of Proteome Research, vol. 6, no. 10, pp. 4055-4062, 2007.
16. G. Candiano, V. Dimuccio, M. Bruschi et al., "Combinatorial peptide ligand libraries for urine proteome analysis: investigation of different elution systems, " Electrophoresis, vol. 30, no. 14, pp. 2405-2411, 2009.
17. G. Chambers, L. Lawrie, P. Cash, and G. I. Murray, "Proteomics: a new approach to the study of disease, " The Journal of Pathology, vol. 192, no. 3, pp. 280-288, 2000.
18. K. Gevaert and J. Wandekerckhove, "Protein identification methods in proteomics, " Electrophoresis, vol. 21, no. 6, pp. 1145-1154, 2000.
19. A. J. Rai, Z. Zhang, J. Rosenzweig et al., "Proteomic approaches to tumor marker discovery, " Archives of Pathology and Laboratory Medicine, vol. 126, no. 12, pp. 1518-1526, 2002.
20. N. Ahmed, G. Barker, K. T. Oliva et al., "Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer, " British Journal of Cancer, vol. 91, no. 1, pp. 129-140, 2004.
21. B. Ye, D. W. Cramer, S. J. Skates et al., "Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry, " Clinical Cancer Research, vol. 9, no. 8, pp. 2904-2911, 2003.
22. W. S. Blaner, "Retinol-binding protein: the serum transport protein for vitaminA, " Endocrine Reviews, vol. 10, no. 3, pp. 308-316, 1989.
23. A. Tschoner, W. Sturm, J. Engl et al., "Retinol-binding protein 4, visceral fat, and the metabolic syndrome: effects of weight loss, " Obesity, vol. 16, no. 11, pp. 2439-2444, 2008.
24. I. Kowalska, M. Straczkowski, A. Adamska et al., "Serumretinol binding protein 4 is related to insulin resistance and nonoxidative glucose metabolism in lean and obese women with normal glucose tolerance, " Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2786-2789, 2008.
25. P. Verner, "Linear ion trap and its application in proteomic analysis, " Chemicke Listy, vol. 99, no. 12, pp. 937-942, 2005.
26. H. O. El-Mesallamy, N. M. Hamdy, A. S. Zaghloul, and A. M. Sallam, "Serum retinol binding protein-4 and neutrophil gelatinase-associated lipocalin are interrelated in pancreatic cancer patients, " Scandinavian Journal of Clinical & Laboratory Investigation, vol. 72, no. 8, pp. 602-607, 2012.
27. D. A. Volmer and L. Sleno, "Mass analyzers: An overview of several designs and their applications, " Spectroscopy, vol. 20, pp. 90-95, 2005.
28. M. Papiz, Z. Sawyer L, E. Eliopoulos et al., "The structure of beta-lactoglobulin and its similarity to plasma retinol-binding protein, " Nature, vol. 255, pp. 561-569, 1988.
29. H. C. Sung, H. K. Soo, B.-S. Youn et al., "High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus, " Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 8, pp. 3142-3148, 2008.
30. K. R. Kozak, F. Su, J. P. Whitelegge, K. Faull, S. Reddy, and R. Farias-Eisner, "Characterization of serum biomarkers for detection of early stage ovarian cancer, " Proteomics, vol. 5, no. 17, pp. 4589-4596, 2005.
31. Y. Xu, Z. Shen, D. W. Wiper et al., "Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers, " Journal of the AmericanMedical Association, vol. 280, no. 8, pp. 719-723, 1998.
32. L. Lorkova, J. Pospisilova, J. Lacheta et al., "Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics, " Oncology Reports, vol. 27, no. 2, pp. 318-324, 2012.
33. K. A. Baggerly, S. R. Edmonson, J. S. Morris et al., "Highresolution serum proteomic patterns for ovarian cancer detection, " Endocrine-Related Cancer, vol. 11, no. 4, pp. 583-587, 2004.
34. J. F. Timms, E. Arslan-Low, A. Gentry-Maharaj et al., "Preanalytic influence of sample handling on SELDI-TOF serum protein profiles, " Clinical Chemistry, vol. 53, no. 4, pp. 645-656, 2007.
35. S. de Ferranti and D. Mozaffarian, "The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences, " Clinical Chemistry, vol. 54, no. 6, pp. 6945-6955, 2008.
36. I. F. Godsland, "Insulin resistance and hyperinsulinaemia in the development and progression of cancer, " Clinical Science, vol. 118, no. 5, pp. 315-332, 2010.
37. Z. Zhang, S. D. Barnhill, H. Zhang et al., "Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses, " Gynecologic Oncology, vol. 73, no. 1, pp. 56-61, 1999.
38. I. Visintin, Z. Feng, G. Longton et al., "Diagnostic markers for early detection of ovarian cancer, " Clinical Cancer Research, vol. 14, pp. 1065-1072, 2008.
39. R. C. Bast Jr., M. Brewer, C. Zou et al., "Prevention and early detection of ovarian cancer:mission impossible?" Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans Les Recherches Sur le Cancer, vol. 174, pp. 91-100, 2007.